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Abstract
Background: S-phase kinase protein 2 (Skp2), an F-box protein, targets cell cycle regulators via ubiquitin-mediated
degradation. Skp2 is frequently overexpressed in a variety of cancers and associated with patient survival. In melanoma,
however, the prognostic significance of subcellular Skp2 expression remains controversial.
Methods: To investigate the role of Skp2 in melanoma development, we constructed tissue microarrays and examined Skp2
expression in melanocytic lesions at different stages, including 30 normal nevi, 61 dysplastic nevi, 290 primary melanomas
and 146 metastatic melanomas. The TMA was assessed for cytoplasmic and nuclear Skp2 expression by immunohisto-
chemistry. The Kaplan-Meier method was used to evaluate the patient survival. The univariate and multivariate Cox
regression models were performed to estimate the harzard ratios (HR) at five-year follow-up.
Results: Cytoplasmic but not nuclear Skp2 expression was gradually increased from normal nevi, dysplastic nevi, primary
melanomas to metastatic melanomas. Cytoplasmic Skp2 expression correlated with AJCC stages (I vs II–IV, P,0.001), tumor
thickness (#2.00 vs .2.00 mm, P,0.001) and ulceration (P=0.005). Increased cytoplasmic Skp2 expression was associated
with a poor five-year disease-specific survival of patients with primary melanoma (P=0.018) but not metastatic melanoma
(P.0.05).
Conclusion: This study demonstrates that cytoplasmic Skp2 plays an important role in melanoma pathogenesis and its
expression correlates with patient survival. Our data indicate that cytoplasmic Skp2 may serve as a potential biomarker for
melanoma progression and a therapeutic target for this disease.
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Introduction
Cutaneous melanoma is an aggressive cancer type originating
from melanocytes in the human skin [1,2]. Although early
diagnosed melanoma is curable with surgical excision, up to
20% of patients will develop metastatic tumors due to its high
capability of invasion and rapid metastasis to other organs [3,4].
Despite many advances in cancer treatment over the last several
decades, the prognosis for patients with advanced melanoma
remains poor. The 5-year survival rate for patients with distant
metastases is less than 10% [5].
The main hallmark of cancer is uncontrolled cellular prolifer-
ation with alterations in the expression or activity of proteins that
are intimately involved in cell cycle regulation, differentiation and
apoptosis [6]. These processes are regulated by transcription,
translation, post-translational modifications and degradation of
key regulatory proteins, and as such, the ubiquitin–proteasome
system has a crucial role in maintaining and regulating cellular
homeostasis [7]. In the ubiquitin–proteasome degradation path-
way, the ubiquitin is transferred and covalently attached to
substrates by the sequential action of three enzymes, namely E1
(ubiquitin-activating enzyme), one of many E2s (ubiquitin-
conjugating enzymes) and one of many E3s (ubiquitin ligases)
[8]. The E3 ligases are mainly classified into two classes on the
basis of structural similarities: the RING-finger proteins and the
HECT-domain proteins [7]. Most of RING-finger type ubiquitin
ligases contain a cullin (Cul) protein subunit, which were also
named as cullin RING ubiquitin ligases (CRLs) [9]. The SCF
(Skp1-Cul1-F-box protein) ubiquitin ligases are the best charac-
terized mammalian CRLs, and the F-box protein provides the
substrate targeting specificity of the complex [10]. Till now, sixty-
nine human F-box proteins that have been identified, and among
them, S-phase kinase-associated protein 2 (Skp2) has emerged as a
key regulator in different cellular processes [7,11]. Skp2 is an
oncogenic protein that targets tumor suppressor proteins for
degradation, including cyclin-dependent kinase (CDK) inhibitors
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Cip1, p27
Kip1 and p57
Kip2 [7,11]. Increased levels of Skp2 and
reduced levels of p27 are observed in many types of cancer, and
these levels are used as independent prognostic markers in several
cases [12].
In melanoma, Li et al. have shown that gain of Skp2 protein
expression are implicated in melanoma progression and Skp2
cytoplasmic expression predicted worse 10-year overall survival in
primary melanoma, suggesting that cytoplasmic expression of
Skp2 defines a subset of aggressive melanomas [13]. The study by
Woenckhaus et al. suggests that Skp2 could contribute to
melanoma progression and vertical growth phase (VGP) melano-
mas show significant higher nuclear Skp2 expression when
compared with the radial growth phase (RGP) [14]. However,
they found that the nuclear but not the cytoplasmic Skp2
expression correlated with a reduced survival time in melanoma
[14]. These studies indicate that Skp2 expression plays a key role
in melanoma development, but the correlation between the sub-
cellular Skp2 expression and melanoma patient survival remains
contradictory which may be due to small sample size in their
studies. To further examine the role of Skp2 subcellular expression
in melanoma development and its prognostic significance, we
evaluated both nuclear and cytoplasmic staining in 30 normal
nevi, 61 dysplastic nevi, 290 primary melanomas and 146
metastatic melanomas.
Materials and Methods
Ethics statement
The use of human skin tissues and the waiver of patient consent
in this study were approved by the Clinical Research Ethics Board
of the University of British Columbia. The study was conducted
according to the principles expressed in the Declaration of
Helsinki.
Patient specimens and tissue microarray construction
TMA construction and immunohistochemistry of TMA were
described elsewhere [15,16]. Briefly, formalin-fixed, paraffin-
embedded tissues from 49 normal nevi, 100 dysplastic nevi, 403
primary melanomas, and 161 metastatic melanomas were used for
our present study. All specimens were obtained from the 1990 to
2009 archives of the Department of Pathology, Vancouver
General Hospital. The most representative tumor area was
carefully selected and marked on the hematoxylin and eosin-
stained slide. The TMAs were assembled using a tissue-array
instrument (Beecher Instruments, Silver Spring, MD). Duplicate
0.6-mm-thick tissue cores were taken from each biopsy specimen.
Multiple 4-mm sections were cut with a Leica microtome (Leica
Microsystems Inc, Bannockburn, IL) and transferred to adhesive-
coated slides. One section from each TMA was routinely stained
with hematoxylin and eosin. The remaining sections were stored at
room temperature for immunohistochemical staining.
Immunohistochemistry of TMA
TMA slides were dewaxed at 55uC for 30 min followed by three
5-min washes with xylene. The rehydration of tissues was
performed by 5-min washes in 100, 95, and 80% ethanol and
distilled water. Antigen retrieval was performed by heating the
samples at 95uC for 30 min in 10 mM sodium citrate (pH 6.0).
Endogenous peroxidase activity was blocked by incubation in 3%
hydrogen peroxide for 30 min. After 30 min blocking with the
universal blocking serum (Dako Diagnostics, Carpinteria, CA), the
sections were incubated with monoclonal mouse anti-Skp2
antibody (1:100 dilution; clone A-2; Santa Cruz Biotechnology,
Santa Cruz, CA) at 4uC overnight. The sections were then
incubated for 30 min each with a biotin-labeled secondary
antibody and then streptavidin-peroxidase (Dako Diagnostics).
The samples were developed using 3,39-diaminobenzidine sub-
Figure 1. CONSORT diagram for patient inclusion and exclusion.
doi:10.1371/journal.pone.0017578.g001
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counterstained with hematoxylin. Dehydration was then per-
formed following a standard procedure and the slides were sealed
with coverslips. Negative controls were performed by omitting the
Skp2 antibody during the primary antibody incubation.
Evaluation of immunostaining
Positive Skp2 immunostaining is defined as either cytoplasmic
or nuclear staining and graded according to both intensity and
percentage of cells with positive staining. The evaluation of Skp2
staining was blindly and independently examined by two
observers, including one dermatopathologist. In few cases with
discrepancy, between the two observers, the immunostained slides
were reviewed in a double viewing microscope so that the
discrepancy was settled. Skp2 staining intensity was scored as 0,
1+,2 +, and 3+. The percentage of Skp2-positive cells was also
scored into 4 categories: 1 (0–25%), 2 (26–50%), 3 (51–75%), and
4 (76–100%). In the cases with a discrepancy between duplicated
cores, the average score from the two tissue cores was taken as the
final score. The level of Skp2 staining was evaluated by
immunoreactive score (IRS) [17], which is calculated by
multiplying the scores of staining intensity and the percentage of
positive cells. Based on the IRS, Skp2 staining pattern was defined
as low staining (0–6) and high staining (8–12).
Statistical analysis
Differences in demographic and clinical characteristics and
expression levels of Skp2 were evaluated by x
2 tests between
patient subgroups. Survival time was calculated from the date of
melanoma diagnosis to the date of death or last follow-up. The
Kaplan-Meier method and log-rank test were used to evaluate the
effects of Skp2 expression on the overall and disease-specific
survival of patients. Univariate or multivariate Cox proportional
hazards regression models were preformed to estimate the crude
hazard ratios (HRs) or adjusted HRs and their 95% confidential
intervals (CIs). SPSS version 11.5 (SPSS Inc, Chicago, IL) software
was used for all analyses.
Results
Increased cytoplasmic Skp2 expression in melanoma
We investigated Skp2 expression in human melanocytic biopsies
using TMA and immunohistochemistry. A total of 713 patients
were enrolled. Due to loss of biopsy cores or insufficient tumor
cells present in the cores, 30 normal nevi, 61 dysplastic nevi, 290
primary melanomas and 146 metastatic melanomas could be
evaluated for Skp2 staining and included in the present study
(Figure 1). For the 436 melanoma cases, there were 258 men and
178 women, with age ranging from 7 to 95 years (median, 60
years). 167 tumors were at AJCC stage I, 123 at stage II, 59 at
stage III, and 87 at stage IV. Among the 290 primary melanoma
cases, 176 tumors were #2.00 mm, and 114 tumors were
.2.00 mm. Ulceration was observed in 53 cases. Seventy-one
melanomas were located in sun-exposed sites (head and neck), and
219 were located in sun-protected sites (other locations) (Table 1).
As shown in Figure 2 and Supporting Information Figure S1,
various levels of cytoplasmic and nuclear Skp2 staining were
observed in nevi and melanoma biopsies. The Skp2 staining was
found consistent when two different antibodies were used in a
small TMA including 20 cases of nevi and 20 case of melanomas
(Supporting Information Figure S2). There are differences in the
pattern of cytoplasmic Skp2 expression in melanocytic lesions at
different stage, with increased levels of expression from normal
nevi to dysplastic nevi and melanoma. Significant differences for
Skp2 staining were observed between normal and dysplastic nevi
(P=0.039, x
2 test), dysplastic nevi and primary melanoma
(P=0.008, x
2 test), and primary and metastatic melanoma
(P=0.008, x
2 test) (Figure 2E). However, there was no significant
Table 1. Cytoplasmic Skp2 staining and clinicopathological
characteristics of melanomas.
Variables Cytoplasmic Skp2 Staining
Low
staining
High
staining Total P
{
All melanoma
(n=436)
Age (years)
#60 126 (56.3%) 98 (43.7%) 224 (51.4%) 0.133
.60 104 (49.1%) 108 (50.9%) 212 (48.6%)
Sex
Male 135 (52.3%) 123 (47.7%) 258 (52.8%) 0.830
Female 95 (53.4%) 83 (46.6%) 178 (47.2%)
AJCC stage
I 112 (67.1%) 55 (32.9%) 167 (38.3%) ,0.001
{
II 54 (43.9%) 69 (56.1%) 123 (28.2%) 0.958
1
III 25 (42.4%) 34 (57.6%) 59 (13.5%)
IV 39 (44.8%) 48 (55.2%) 87 (20.0%)
Primary
melanoma
(n=290)
Age (years)
#60 84 (60.4%) 55 (39.6%) 139 (47.9%) 0.292
.60 82 (54.3%) 69 (45.7%) 151 (52.1%)
Sex
Male 89 (56.3%) 69 (43.7%) 158 (54.5%) 0.731
Female 77 (58.3%) 55 (41.7%) 132 (45.5%)
Tumor thickness
(mm)
#2.00 118 (67.0%) 58 (33.0%) 176 (60.7%) ,0.001
.2.00 48 (42.1%) 66 (57.9%) 114 (39.3%)
Ulceration
Absent 141 (59.5%) 96 (40.5%) 237 (81.7%) 0.005
Present 25 (47.2%) 28 (52.8%) 53 (18.3%)
Site*
Sun-protected 124 (56.6%) 95 (43.4%) 219 (75.5%) 0.707
Sun-exposed 42 (59.2%) 29 (40.8%) 71 (24.5%)
Metastatic
melanoma
(n=146)
Age (years)
#60 42 (49.4%) 43 (50.6%) 85 (58.2%) 0.109
.60 22 (36.1%) 39 (63.9%) 61 (41.8%)
Sex
Male 46 (46.0%) 54 (54.0%) 100 (68.5%) 0.437
Female 18 (39.1%) 28 (60.9%) 46 (31.5%)
*Sun-protected sites: trunk, arm, leg and feet; Sun-exposed sites: head and neck.
{x
2 test.
{Comparison between all AJCC stages.
1Comparison between AJCC stage II, III and IV.
doi:10.1371/journal.pone.0017578.t001
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melanocytic lesions (P.0.05, x
2 test) (Figure S1).
Cytoplasmic Skp2 expression correlates with AJCC
stages, tumor thickness and ulceration
Since cytoplasmic Skp2 expression was correlated with
melanoma progression, we next examined the correlation between
cytoplasmic Skp2 expression and different clinicopathologic
characters. As shown in Figure 3A and Table 1, high expression
of cytoplasmic Skp2 was detected in 33% of melanomas at AJCC
stage I compared to only 55–58% of melanomas at AJCC II, III
and IV (P,0.001, x
2 test); however, no significant difference was
found in Skp2 expression between AJCC stage II and III or IV,
indicating that increased cytoplasmic Skp2 expression may be
involved in the melanoma development from stage I to II. In
addition, we found that the cytoplasmic Skp2 expression was
correlated with Ki67 expression, the proliferative index (Support-
ing Information Figure S3), and inversely correlated with nuclear
p27 expression, a cyclin-dependent kinase inhibitor for cell cycle
progression (Supporting Information Figure S4). These data
suggest that cytoplasmic Skp2 regulates melanoma progression
may through promoting melanoma cell cycle progression.
There was no correlation between cytoplasmic Skp2 expression
and age or sex in all melanoma patients (Table 1). In primary
melanoma, high cytoplasmic Skp2 expression was found in 58% of
tumors with thickness .2.00 mm, compared to 33% of melano-
mas with thickness #2.00 mm (P,0.001, x
2 test; Figure 3B).
Increased cytoplasmic Skp2 expression was correlated with
Figure 2. Cytoplasmic Skp2 expression is increased in human
melanomas. Representative images of cytoplasmic Skp2 immunohis-
tochemical staining in human melanocytic lesions. (A and C) Low
cytoplasmic Skp2 staining, (B and D) High cytoplasmic Skp2 staining. (E)
Cytoplasmic Skp2 expression is increased from normal nevi to
dysplastic nevi and melanoma. Significant differences for Skp2 staining
are observed between normal and dysplastic nevi (P=0.039, x
2 test),
dysplastic nevi and primary melanoma (P=0.008, x
2 test), and primary
and metastatic melanoma (P=0.008, x
2 test). NN, normal nevi; DN:
dysplastic nevi; PM: primary melanoma; MM: metastatic melanoma.
Magnification: 6100 for A and B; 6400 for C and D.
doi:10.1371/journal.pone.0017578.g002
Figure 3. Cytoplasmic Skp2 correlates with melanoma AJCC
stages, tumor thickness and ulceration. (A) Tumors in AJCC stages
II, III and IV have a higher percentage of high cytoplasmic Skp2
expression compared with tumors in stage I (P,0.001, x
2 test). (B)
Tumors thicker than 2.0 mm have a higher percentage of high
cytoplasmic Skp2 expression compared with tumors #2.0 mm thick
(P,0.001, x
2 test). (C) Increased cytoplasmic Skp2 expression is
correlated with ulceration of melanoma (P=0.005, x
2 test).
doi:10.1371/journal.pone.0017578.g003
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2 test; Table 1). We did not
find significant correlations between cytoplasmic Skp2 expression
and other variables (Table 1). In addition, cytoplasmic Skp2
expression was not correlated with age or sex in metastatic
melanoma (Table 1).
Increased cytoplasmic Skp2 expression is associated with
poor patient survival
A total of 392 patients had complete follow-up and clinical
information (Figure 1). Demographic and clinical characteristics
of the patients were listed in Table 2 and Supporting Information
Table S1 and S2. The Kaplan-Meier curve and log-rank test
analyses revealed that increased cytoplasmic Skp2 expression was
associated with poor overall (P=0.025) or disease-specific five-
year survival (P=0.035) (Figure 4A and B). Next, we separated all
melanoma (n=392) into primary melanoma (n=259) and
metastatic melanoma (n=133) and found cytoplasmic Skp2
expression was associated with overall (P=0.025) and disease-
specific five-year survival (P=0.018) in primary melanoma
patients (Figure 4C and D). However, cytoplasmic Skp2
expression was not associated with overall and disease-specific
five-year survival in metastatic melanoma patients (P.0.05 for
both) (Figure 4E and F). Since previous study showed that nuclear
Skp2 expression was associated with melanoma patient survival
[14], we also examined the correlation between nuclear Skp2
expression and patient survival. The results indicate that nuclear
Skp2 expression is not associated with overall and disease-specific
five-year survival in all melanoma, primary melanoma or
metastatic melanoma patients (Supporting Information Figure
S5).
Next, we used univariate Cox proportional hazards regression
model to estimate the crude hazard ratios (HRs) of Skp2
expression or each clinicopathologic variable on patient survival.
The log-rank test and univariate Cox regression analyses revealed
that both AJCC stages and cytoplasmic Skp2 expression were
significantly associated with overall or disease-specific survival in
all melanoma patients (Supporting Information Table S1). In
primary melanoma patients, age, tumor thickness, ulceration and
cytoplasmic Skp2 expression were all significantly associated with
both overall and disease-specific survival (Table 2). However, the
nuclear expression was not associated with either overall or
disease-specific survival outcomes (Table 2). In metastatic
melanoma patients, both cytoplasmic and nuclear expressions
were not associated with either overall or disease-specific survival
(Supporting Information Table S2).
Cytoplasmic Skp2 expression is not an independent
prognostic marker for primary melanoma
Since cytoplasmic Skp2 was associated with melanoma patient
survival, we next examined whether cytoplasmic Skp2 expression
is an independent prognostic marker for melanoma patient
survival by multivariate Cox proportional hazard analysis. Age,
sex, tumor thickness, ulceration and location and cytoplasmic
Skp2 expression were included in the regression model. The
Table 2. Univariate Cox proportional regression analysis on overall and disease-specific 5-year survival of 259 primary melanoma
patients.
Variable Patients (%) Overall survival Disease-specific survival
Deaths Death Rate HR (95% CI) P
{ Deaths Death Rate HR (95% CI) P
{
Age
#60 124 (47.9%) 21 16.9% 2.65 (1.58–4.42) ,0.001 21 16.9% 2.14 (1.26–3.65) 0.005
.60 135 (52.1%) 48 35.6% 39 28.9%
Sex
Male 138 (53.3%) 37 26.8% 1.00 (0.62–1.61) 0.994 34 24.6% 0.89 (0.53–1.48) 0.645
Female 121 (46.7%) 32 26.4% 26 21.5%
Thickness (mm)
#2.00 152 (58.7%) 22 14.5% 4.32 (2.60–7.19) ,0.001 17 11.2% 5.09 (2.89–8.94) ,0.001
.2.00 107 (41.3%) 47 43.9% 43 40.2%
Ulceration
Absent 211 (85.3%) 42 19.9% 4.64 (2.84–7.59) ,0.001 37 17.5% 4.43 (2.61–7.51) ,0.001
Present 48 (14.7%) 27 56.3% 23 47.9%
Site*
Sun-protected 196 (75.7%) 53 27.0% 1.00 (0.57–1.76) 0.990 44 22.4% 1.21 (0.68–2.14) 0.515
Sun-exposed 63 (24.3%) 16 25.4% 16 25.4%
Cytoplasmic Skp2
Low staining 145 (56.0%) 30 20.7% 1.71 (1.07–2.76) 0.027 25 17.2% 1.84 (1.10–3.08) 0.020
High staining 114 (44.0%) 39 34.2% 35 30.7%
Nuclear Skp2
Low staining 60 (23.2%) 21 35.0% 0.65 (0.39–1.09) 0.100 19 31.7% 0.62 (0.36–1.06) 0.080
High staining 199 (76.8%) 48 24.1% 41 20.6%
*Sun-protected sites: trunk, arm, leg and feet; Sun-exposed sites: head and neck.
{Log-Rank test. Abbreviations: HR, hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0017578.t002
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associated with both overall and disease-specific survival (P.0.05
for both, Table 3). As expected, cytoplasmic Skp2 expression was
not associated with survival in all melanoma patients by
adjustment with AJCC stages, age and sex (Supporting Informa-
tion Table S3). These data indicate that cytoplasmic Skp2 staining
is not independent prognostic factor for five-year survival of
melanoma patients.
Discussion
Melanocytes are located in the skin, eyes and other epithelial
tissues and are the precursors of benign nevus and melanoma
[18,19]. The highly differentiated benign nevi have a low
proliferation potential and retain melanin production, whereas
malignant melanoma show increased proliferation and may have
partly or fully lost the ability to synthesize melanin, in parallel with
Figure 4. Cytoplasmic Skp2 expression is associated with five-year survival of all melanoma and primary melanoma patients.
Kaplan-Meier curves analyses for the correlation between cytoplasmic Skp2 expression and overall or disease-specific five-year survival in all
melanoma patients (A,B), primary melanoma patients (C,D) and metastatic melanoma patients (E,F).
doi:10.1371/journal.pone.0017578.g004
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proliferation signaling, including mitogen-activated protein kinase
(MAPK) pathway, induces malignant transformation of melano-
cytes to melanoma [20]. Due to their relatively small size, variable
criteria for histological diagnosis, controversial terminology, and
difficulty in establishing in vitro cultures, melanocytic dysplastic
nevi have hardly been studied [21]. The limited studies on
dysplastic nevi mainly focus on some genetic changes [22]. In
addition to genetic changes, recent studies indicate that the
alterations of tumor suppressor, onco-proteins and growth factors
contribute to development of dysplastic nevi from normal nevi and
suggest that evolution of some dysplastic nevi may result in
primary melanoma [23,24]. Our study showed that cytoplasmic
Skp2 expression was gradually increased from normal nevi,
dysplastic nevi to melanoma tissues, indicating that increased
cytoplasmic Skp2 expression may be involved in the development
of dysplastic nevi and melanoma. Skp2 has oncogenic potential
and is overexpressed in human cancers [25]. To our knowledge,
this study for the first time showed that cytoplasmic Skp2 plays a
key role in both melanoma initiation and progression.
Mutations in BRAF, a regulator of the mitogen-activated
protein-kinase kinase (MAPKK)-ERK1/2 pathway, are associated
with approximately 70% of melanomas; the most common
mutants are BRAF
V599E and BRAF
V600E [26,27]. In melanoma
cells, mutation in BRAF constitutively activates BRAF signaling,
which regulates Cks1/Skp2-mediated p27 degradation and
controls G1 cell cycle event [28,29]. In human thyroid
carcinomas, constitutive signaling of the MAP kinase cascade
contributes to the development of thyroid cancer promoted by
activated RAS and BRAF onco-proteins and that this occurs, at
least in part, by compromising the Skp2-dependent degradation
pathway [30]. Our study showed that cytoplasmic Skp2 expression
was increased in melanoma, which may be due to BRAF
mutation. In addition, increased copy number at the Skp2 locus
might also be associated with overexpression of Skp2 protein in
human metastatic melanoma tissues [31].
In primary melanoma, we found a correlation between the
depth of tumor invasion (thickness), ulceration and cytoplasmic
Skp2 expression in the primary melanoma, which suggests a role
of Skp2 in tumor invasion. It has been reported that overexpres-
sion of Skp2 correlated with metastasis in different cancers
including colorectal tumors, lung cancers, oral and esophageal
squamous cell carcinoma, human gastric carcinoma and pancre-
atic ductal adenocarcinoma [32,33,34,35,36,37,38,39]. Skp2
regulates invasive ability of melanoma cells [40] and overexpres-
sion of Skp2 correlates with advanced melanoma [31]. Li et al.
found that Skp2 phosphorylation by Akt triggers SCF complex
formation and E3 ligase activity, promotes cell proliferation and
tumorigenesis [41]. Akt-mediated phosphorylation triggers 14-3-3
beta-dependent Skp2 relocalization to the cytosol and positively
regulates cell migration. Furthermore, high levels of activation of
Akt correlate with the cytosolic accumulation of Skp2 in human
colonic adenocarcinoma. In addition, Skp2 overexpression
induces the expression of matrix metalloproteinase (i.e. MMP-2,
MMP-9) and invasion of lung cancer cells [42]. Thus, increased
cytoplasmic Skp2 expression contributes to melanoma invasion
possibly through multiple pathways since both Akt and MMP
proteins play import roles in melanoma invasion and metastases
[16,43,44].
Cytoplasmic but not nuclear Skp2 expression was associated
with five-year overall and disease-specific survival in primary
melanoma patients. This finding was consistent with the study by
Li et al. that high cytoplasmic but not nuclear Skp2 expression
predicted worse 10-year overall survival in primary melanoma
[13]. However, Woenckhaus et al. found that increased nuclear
Skp2 expression correlates with a reduced survival time in
melanoma [14]. The controversial findings may be due to a
relative small number of patients (n=25) for the survival analysis
in the study by Woenckhaus et al. Recent study by Rose et al.
showed that high Skp2 expression (.25% Skp2 staining) predicted
worse seven-year post-recurrence survival when comparing low
Skp2 expression (#25% Skp2 staining) in 93 cases of metastatic
melanoma patients [31]. In our study, neither nuclear nor
cytoplasmic Skp2 expression was associated with five-year survival
in 133 cases of metastatic melanoma patients. The clarification on
the correlation between Skp2 expression and survival in metastatic
melanoma patients awaits future study with a longer follow-up
time.
Although surgical removal has been reported with cure rate
over 80% for stage I melanoma and as high as 98% for melanoma-
in-situ [45,46], there is no effective treatment for advanced
melanoma, It is important to understand the molecular mecha-
nisms of melanoma development and provides a necessary basis to
enable the generation of more effective therapeutic modalities. We
found that cytoplasmic Skp2 expression is increased in melanoma
and the increased cytoplasmic Skp2 expression correlated with
Table 3. Multivariate Cox regression analysis on overall and disease-specific 5-year survival of 259 primary melanoma patients.
Variables* Overall survival Disease-specific survival
b
{ SE HR 95% CI P
{ b
{ SE HR 95% CI P
{
Age 0.544 0.278 1.74 1.01–3.02 0.046 0.282 0.289 1.33 0.75–2.34 0.329
Sex 0.012 0.254 1.01 0.62–1.66 0.964 –0.060 0.276 0.94 0.55–1.62 0.828
Thickness 1.035 0.295 2.82 1.58–5.02 ,0.001 1.241 0.324 3.46 1.83–6.53 ,0.001
Ulceration 0.908 0.282 2.48 1.43–4.31 0.001 0.884 0.301 2.42 1.34–4.37 0.003
Location –0.091 0.292 0.91 0.52–1.62 0.755 0.100 0.301 1.11 0.61–2.00 0.740
Cytoplasmic Skp2 0.124 0.258 1.13 0.68–1.88 0.629 0.177 0.277 1.19 0.69–2.05 0.523
*Coding of variables: Age was coded as 1 (#60 years) and 2 (.60 years). Sex was coded as 1 (male) and 2 (female). Thickness was coded as 1 (#2.00 mm) and 2
(.2.00 mm). Ulceration was coded as 1 (absent) and 2 (present). Location was coded as 1 (sun-protected) and 2 (sun-exposed). Cytoplasmic Skp2 was coded as 1 (low
staining) and 2 (high staining).
{b: regression coefficient.
{Log-Rank test.
Abbreviations: SE, standard error of b; HR, hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0017578.t003
Skp2 Expression in Melanoma
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17578melanoma development. In melanoma, Skp2 plays a key role in
promoting cell cycle progression [47,48,49,50]. Katagiri et al.
reported that knockdown of Skp2 inhibited the melanoma cell
growth in vitro and suppressed tumor proliferation in vivo,
suggesting that gene silencing of Skp2 can be a potential tool of
cancer gene therapy in malignant melanoma [51]. Another study
by Sumimoto et al. revealed that the combined suppression of
BRAF
V599E and Skp2 inhibited cell growth and attenuated the
invasive potential of melanoma cell lines in vitro prompting
speculation regarding the possibility of combination therapy
targeting BRAF and Skp2 [40]. Thus, targeting Skp2 in gene
therapy may hold promise for melanoma treatment.
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